Rocket Pharmaceuticals (NASDAQ:RCKT) Stock Price Expected to Rise, Chardan Capital Analyst Says
Rocket Pharmaceuticals (NASDAQ:RCKT – Free Report) had its target price increased by Chardan Capital from $45.00 to $46.00 in a report released on Friday morning,Benzinga reports. Chardan Capital currently has a buy rating on the biotechnology company’s stock. Chardan Capital also issued estimates for Rocket Pharmaceuticals’ FY2025 earnings at ($2.32) EPS and FY2026 earnings at […]
Rocket Pharmaceuticals (NASDAQ:RCKT – Free Report) had its target price increased by Chardan Capital from $45.00 to $46.00 in a report released on Friday morning,Benzinga reports. Chardan Capital currently has a buy rating on the biotechnology company’s stock. Chardan Capital also issued estimates for Rocket Pharmaceuticals’ FY2025 earnings at ($2.32) EPS and FY2026 earnings at […]
